@nadahamad Awwww. I was so excited to hear @sholzberg give a nod to you, @nadahamad, in her incredible educational session, addressing structural sexism in hematology. World collide! 🥰❤️
If you spent Christmas with your loved ones virtually and sacrificed in-person gatherings because you wanted to protect them, RT this.
Trying to prove something.
Can treating COVID-19 patients with higher doses of heparin help save lives? Our Drs. Michelle @sholzberg and Peter Jüni and @UVMMedCenter’s @MaryCushmanMD will find out.
Here’s how you can support them in meeting the needs of patients globally: https://t.co/IIaEATHkWr.
Our #COVID19 Registry for Hematologic Malignancy is a global registry targeted on understanding the impact of COVID-19 on patients with hematologic malignancies. Learn more about the Registry to help inform care for people w/ blood cancers. https://t.co/gD2PLZhNtE #ASHCOVID
Hundreds of hungry monkeys swarm across Thai street as 'rival gangs' fight over food after tourists who normally feed them stay away because of coronavirus https://t.co/lQZ0sOzwDF
Our @SWOG S1826 trial for patients with advanced stage Hodgkin lymphoma ages 12 years and above is open and accruing in all NCTN groups. Encouraging participation of everyone; study will also open in Canada later this year. https://t.co/3BS5UICvBR
If only the world was led by children. This is a note left to me this morning by my seven year old daughter Poppy. Her little sister is Orlaith, who is two years old with Autism. ❤️ #flipthenarrative#senco#autism#edutwitter
I wrote this in reaction to the loss of one of my patients - originally written in despair & with a deep sense of failure. I later found hope & direction. Thank you to the voices of #hemetwitter. For our patients, for their families & for ourselves - it is time to ditch “benign”
RCHOP in DLBCL remains the standard. Updated after #ASH18
Pivotal phase III trials over the last 18 years (HRs for OS comparison of challengers vs. RCHOP21). #lymsm#lymphoma
Great to see @ALLIANCE_org upfront CLL study being presented at #ASH18 plenary session - practice changing results, public funding and scientific leadership from the US National Clinical Trials Network (NCTN) @theNCI@NCIMedia@NCIDirector
Lost opportunity! IDA unrecognized, IV iron provided provided 2 weeks prior to delivery. WE CAN DO BETTER! Phenomenal work by @JeannieCallum @hvandermeulen#ASH18